Current Infectious Disease Reports

, 11:435

First online:

New immunosuppressive agents and risk for invasive fungal infections

  • Georg MaschmeyerAffiliated withDepartment of Hematology, Oncology, and Palliative Care, Klinikum Ernst von Bergmann Email author 
  • , Thomas F. Patterson

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Increased numbers of invasive fungal infections (IFI) were reported in patients treated with newer immunosuppressive drugs such as tumor necrosis factor (TNF)-α antagonists, the anti-CD52 antibody alemtuzumab, or the interleukin-2 receptor antibody basiliximab. These drugs are administered to patients who have autoimmune inflammatory diseases and lymphoid malignancies, or are recipients of solid organ or allogeneic hematopoietic stem cell transplants. IFI risk is higher in patients receiving TNF-α blockers or alemtuzumab late in the course of disease and in those with a history of IFI. Incidence and mortality rates of IFI are confounded by frequent, multiple comedications, heterogeneous definitions for IFI, and a presumed reporting bias. For filamentous molds and endemic fungal infections, different regional prevalence rates must be considered. Generally, invasive infections are more frequent among these groups and thus are important considerations in the management of patients receiving these immunosuppressive drugs.